Ionis Pharmaceuticals Newsroom

Analysts Offer Insights on Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP), Ionis Pharmaceuticals (IONS) and Zura Bio (ZURA)

TipRanksDec 25 19:51 · Ratings

Are Investors Undervaluing Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) By 30%?

Yahoo FinanceDec 23 21:42

PANTHERx Rare Selected by Ionis as Specialty Pharmacy for TRYNGOLZA (Olezarsen)

PR NewswireDec 23 21:42

Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $62

Futu NewsDec 23 20:31 · Ratings

Barclays Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Maintains Target Price $51

Futu NewsDec 23 18:31 · Ratings

Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and UnitedHealth (UNH)

TipRanksDec 23 17:40 · Ratings

Express News | Ionis Pharmaceuticals Inc : Oppenheimer Raises Target Price to $78 From $75

BreakingsDec 23 13:26

A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $59 to $67

Futu NewsDec 21 21:00 · Ratings

Ionis Pharmaceuticals' Growth Prospects Bolstered by FDA Approval of Tryngolza

TipRanksDec 21 02:13

Sector Update: Health Care Stocks Mixed Premarket Friday

MT NewswiresDec 20 22:04

The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 Experts

BenzingaDec 20 22:01

Needham Maintains Buy on Ionis Pharmaceuticals, Maintains $60 Price Target

BenzingaDec 20 20:18 · Ratings

Ionis Pharmaceuticals Analyst Ratings

BenzingaDec 20 20:16 · Ratings

Ionis Pharmaceuticals Says FDA Approved Familial Chylomicronemia Syndrome Drug

MT NewswiresDec 20 17:36

The rare disease drug Olezarsen under Ionis Pharmaceuticals (IONS.US) has been approved by the FDA.

The FDA has approved Olezarsen, a product of Ionis Pharmaceuticals, for the treatment of familial chylomicronemia syndrome (FCS).

Zhitong FinanceDec 20 15:28

Trading Halt: Halt Status Updated at 6:55:00 PM ET: Quotation Resumption: News and Resumption Times

BenzingaDec 20 07:55

Express News | Ionis Pharmaceuticals Inc - Tryngolza to Be Available in U.S. Before Year End

BreakingsDec 20 07:29

TRYNGOLZA (Olezarsen) Approved in U.S. as First-ever Treatment for Adults Living With Familial Chylomicronemia Syndrome as an Adjunct to Diet

PR NewswireDec 20 07:28

Trading Halt: Halted at 4:28:30 P.m. ET - Trading Halt: Halt News Pending

BenzingaDec 20 05:28

New Strategy? Cathie Wood's ARK Purchases Shares in Futu, Significantly Increased Its Stake in AI Healthcare Company Tempus AI and Sold Off Shopify

Cathie Wood's ARK ETF announced the daily Trade details for Tuesday, December 17, 2024.

Futu NewsDec 18 18:22